Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q4 CY2024, with sales falling 32.8% year on year to ...

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Revenue of $39.2 million, a 33% ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results tomorrow after market ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent 2024 preliminary results and restructuring ...

CEO Christian Henry highlighted Q4 2024 revenue of $39.2 million, driven by the shipment of 23 Revio systems and the early shipment of seven Vega benchtop platforms, which exceeded schedule. Full-year ...

EST Cathie Wood’s ARK Investment bought 344K shares of PacBio (PACB) todayMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California, Inc. ( NASDAQ: PACB) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - ...

PacBio’s earnings surpassed the Zacks Consensus ... Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is among the most innovative ...